Absolute Antibody and University of Zurich partner to offer novel SARS-CoV-2 sybodies

Absolute Antibody Ltd., an industry-leading provider of recombinant antibody products and services, today announced a partnership with University of Zurich to offer synthetic nanobodies against the receptor binding domain (RBD) of SARS-CoV-2, the coronavirus that causes COVID-19. Under the partnership, the original nanobodies and newly engineered formats are now available to the global research community for use as serological controls and in COVID-19 therapeutic development. The synthetic nanobodies possess particular promise for the development of inhalable drugs, which could offer a convenient treatment option for the COVID-19 pandemic.

Nanobodies are small antibody fragments that can reach previously inaccessible parts of the body due to their compact size. Researchers are exploring their potential as inhalable COVID-19 drugs, which would be easier to administer and reach patients’ lungs faster than other treatment formulations. The laboratory of Markus Seeger at University of Zurich developed a rapid in vitro selection platform to generate synthetic nanobodies, known as sybodies, against the receptor binding domain (RBD) of SARS-CoV-2. Within a two-week timeframe, the lab had identified more than 60 unique anti-RBD sybodies from combinatorial display libraries.

Further research showed that six of the sybodies bound SARS-CoV-2 spike protein with very high affinity, while five of those also inhibited ACE2, the host cell receptor to which SARS-CoV-2 binds to initiate the COVID-19 infection. Moreover, two of the sybodies can simultaneously bind the RBD, which could enable the construction of a polyvalent antiviral drug. The SARS-CoV-2 sybodies are therefore valuable tools for coronavirus research, diagnostics and therapeutic development, and the panel is now available to researchers worldwide via Absolute Antibody’s online catalog.

Absolute Antibody recombinantly produces the SARS-CoV-2 synthetic nanobodies for ensured batch-to-batch reproducibility, high purity and low endotoxin levels. In addition, Absolute Antibody has used antibody engineering to fuse the nanobodies to Fc domains in different species, isotypes and subtypes. For example, the anti-RBD binders are now available with human IgG1, IgG3, IgM and IgA domains for use as serological controls. These recombinant engineered antibodies extend the applications of the sybodies by varying effector function and permitting increased half-life in in-vivo studies.

We are excited to partner with the Seeger lab to make their novel synthetic nanobodies more widely available to the research community. Combined with Absolute Antibody’s unique antibody engineering approach, we can harness even more potential from the nanobodies and help scientists worldwide fight against the COVID-19 pandemic.”

Dr. Michael Fiebig, Vice President Product Portfolio & Innovation at Absolute Antibody

The global research community has been working at unprecedented speeds to fight COVID-19. By partnering with Absolute Antibody, we have extended the reach and applications of our new synthetic nanobodies, furthering their potential in the race to develop urgently required therapeutics.”

Dr. Markus Seeger, Professor at the Institute of Medical Microbiology of the University of Zurich

In addition to the new synthetic antibodies, Absolute Antibody offers a variety of other engineered reagents for coronavirus research, including SARS-CoV-2 spike glycoprotein and nucleoprotein antibodies, ACE2 Fc fusion proteins, and anti-human immunoglobulin antibodies for use in diagnostic tests. Absolute Antibody is also supporting coronavirus research by providing antibody engineering and manufacturing services, such as the production of gram quantities of human antibodies sequenced from recovering COVID-19 patients.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Absolute Antibody Ltd. (2020, July 14). Absolute Antibody and University of Zurich partner to offer novel SARS-CoV-2 sybodies. News-Medical. Retrieved on October 01, 2022 from https://www.news-medical.net/news/20200714/Absolute-Antibody-and-University-of-Zurich-partner-to-offer-novel-SARS-CoV-2-sybodies.aspx.

  • MLA

    Absolute Antibody Ltd. "Absolute Antibody and University of Zurich partner to offer novel SARS-CoV-2 sybodies". News-Medical. 01 October 2022. <https://www.news-medical.net/news/20200714/Absolute-Antibody-and-University-of-Zurich-partner-to-offer-novel-SARS-CoV-2-sybodies.aspx>.

  • Chicago

    Absolute Antibody Ltd. "Absolute Antibody and University of Zurich partner to offer novel SARS-CoV-2 sybodies". News-Medical. https://www.news-medical.net/news/20200714/Absolute-Antibody-and-University-of-Zurich-partner-to-offer-novel-SARS-CoV-2-sybodies.aspx. (accessed October 01, 2022).

  • Harvard

    Absolute Antibody Ltd. 2020. Absolute Antibody and University of Zurich partner to offer novel SARS-CoV-2 sybodies. News-Medical, viewed 01 October 2022, https://www.news-medical.net/news/20200714/Absolute-Antibody-and-University-of-Zurich-partner-to-offer-novel-SARS-CoV-2-sybodies.aspx.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment